Head of In Silico Medicinal Chemistry

Institute of Cancer Research - Medicinal Chemistry 1 (Analytical Chemistry and In Silico Chemistry)

The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally.

The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.

The Cancer Research UK Cancer Therapeutics Unit (CTU), within the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 160 staff dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer. We are probably the largest academic cancer drug discovery group in the world and, since 2010, 9 drugs discovered by CTU scientists, either alone or in collaboration with a commercial partner, have been studied in our ICR/Royal Marsden Drug Development Unit. Our drug abiraterone has been approved in the US, Canada and Europe for late stage prostate cancer.

Our drug discovery is carried out in highly focused multi-disciplinary project teams, analogous to those in a biotechnology company, with patient benefit as the primary driver. Our team of 4 in silico medicinal chemists work alongside, chemists, structural biologists, cancer biology, drug metabolism and computational biology experts focusing on new molecular targets emerging from basic cancer biology research and clinical studies. We publish our work extensively and have a large network of collaborations with academia, biotechnology companies, and the pharmaceutical industry. Following a recent international peer review exercise, our work was rated as ‘Forefront/Outstanding’.

A position in the CTU is now available to lead the In Silico Medicinal Chemistry team to accelerate the progression of small molecule drug discovery projects by appropriate development and application of in silico medicinal chemistry methods. The successful candidate will be expected to both lead the team and be pro-actively and directly involved in the application of computational methods to enhance our screening libraries and to progress our portfolio of drug discovery projects from hit discovery to the selection of preclinical development candidates.

Informal enquiries should be made to julian.blagg@icr.ac.uk

To Apply for the post and to view the job description please click below. 

We consider all applications on merit and have a strong commitment to enhancing the diversity of our staff. We particularly welcome applications from women and people from ethnic minorities, as they are under-represented at the ICR at this level.
Share this job
     
  Share by Email   Print this job   More sharing options
We value your feedback on the quality of our adverts. If you have a comment to make about the overall quality of this advert, or its categorisation then please send us your feedback
Advert information

Location(s):

South East England